New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:56 EDTJNJJohnson & Johnson sees FY net interest expense $400M-$500M
Says early Q1 data shows continued softer utilization trends impacted by the severe winter conditions. Says data shows continued slight declines in the rates of surgical and lab procedures in the U.S., similar to what was seen over the past 12 months. Says strong Q4 utilization in orthopedic procedures softened in Q1 due to some seasonality. Says confident overall about the long-term health of the market as economic conditions continue to recover. Says Japanese yen to be a headwind in 2014, although that negative impact to gross margin will increase throughout the year. Sees FY14 net interest expense $400M-$500M, effective tax rate 19%-20%. Says guidance for 2014 anticipates that the R&D tax credit will be renewed by Congress. Says expects continued pricing pressure in 2014 across many markets, particularly in Europe; says impact of this negative pricing pressure to negatively impact pretax operating margin by approximately 50bps. Says "comfortable" with models reflecting an operational sales increase on a constant currency basis of 5%-6% for the year. Says if currency exchange rates for all of 2014 were to remain where they were as of last week, sales growth rate would decrease by nearly half a percent. Says this would result in sales for 2014 on a constant currency basis of approximately $74.9B-$75.7B. Says that if exchange rates for all of 2014 were to remain where they were as of last week, then our reported EPS excluding special items would be positively impacted by approximately 6c per share due solely to exchange rate fluctuations. Comments made on the Q1 earnings conference call.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 18, 2014
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 12, 2014
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
August 8, 2014
09:01 EDTJNJJohnson & Johnson remains undervalued, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use